Background Osteoporosis is a systemic skeletal disorder and occurs frequently in
postmenopausal women and older men. This study aimed to examine whether diosmetin …

Our previous studies showed that dioscin can promote osteoblasts proliferation and
differentiation in vitro, but its anti-osteoporosis effect in vivo and the underlying mechanisms …

Osteolytic bone diseases are closely linked to the over‐activation of osteoclasts and
enhancement of bone resorption. It has become a major health issue in orthopedic practice …

Secondary osteoporosis is commonly caused by long-term intake of glucocorticoids (GCs),
such as dexamethasone (DEX). Diosmin, a natural substance with potent antioxidant and …

Aim Due to on-going safety concerns or lack of efficacy of currently used medications for the
treatment of osteoporosis (OP), identifying new therapeutic agents is an important part of …

Postmenopausal osteoporosis (PMO) has become a public health problem worldwide.
Hormonal replacement therapy (HRT) is the most popular treatment for PMO at present, but …

Abstract Background and Objective: Loss of ovarian function after menopause affects bone
metabolism and structure. The present study examined the synergistic effects of Estradiol …

Osteoporosis is a highly prevalent bone metabolic disease in menopause due to estrogen
deficiency. Hyperoside is a main compound in Semen cuscutae. Our team previously …

Aims Postmenopausal osteoporosis (PMOP) is a growing health problem affecting many
postmenopausal women. This study intended to identify the role of dexmedetomidine (Dex) …

Objective Secoisolariciresinol diglucoside (SDG) is a phytoestrogen that has been reported
to improve postmenopausal osteoporosis (PMOP) caused by estrogen deficiency. In our …